New England Journal of Medicine, Volume 372, Issue 10, Page 981-982, New England Journal of Medicine, 1 day ago
Patients with Large-Vessel Abnormalities Present Diagnostic Dilemma for Rheumatologists - The-Rheumatologist.org, 2 weeks ago
2 images for "dyspnea"
Betty suffers from the disabling dyspnea of her advanced COPD. Despite use of oxygen, opioid analgesics, and antianxiety agents, Betty finds that her fear of breathlessness worsens her anxiety, making her breathing more difficult. Twice weekly ...Advance For NPs And PAs, 2 weeks ago
An 81-year-old man presented with a 1-week history of dry cough. He also complained of mild dyspnea, wheezing, and low-grade fever. He denied hemoptysis, fever, rashes, or chest pain. The patient's medical history included coronary artery bypass ...CHEST, 1 month ago A 55-Year-Old Man With a Small Right Lung and a Right-Sided Heart CHEST, 2 days ago Lung Herniation with Coughing New England Journal of Medicine, 1 month ago
Your NEJM Group Today: Case of Abdominal Pain, Dyspnea, & Diplopia; Statins in Men and Women; Washington IM Opportunity — Physician's First WatchYour NEJM Group Today: Case of Abdominal Pain, Dyspnea, & Diplopia; Statins in Men and Women; ...24Dunia, 1 month ago
General Please address all your queries or problem reports to the Pay-per-View Customer Service at firstname.lastname@example.org referring to PPV or PPV account. 1. All payments are by credit card only. The transaction is secure: standard-procedure SSL or ...Karger.com, 1 month ago
Eisai Company, Ltd. And Merck & Co. Enter Collaboration To Explore Novel Combination Regimens Of Anti-PD-1 Therapy With Multi-Targeting RTK Inhibitor And Microtubule Dynamics Inhibitor In Multiple Types Of Cancer
Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a ...BioSpace, 8 hours ago Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer World Energy Source, 1 day ago MERCK : Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer 4 Traders, 1 day ago
Carfilzomib helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened, when compared to a regimen containing rival drug bortezomib in a planned interim analysis. The results from a planned interim ...Ecancer Medicalscience, 10 hours ago Kyprolis Doubles Progression-Free Survival Over Velcade in Multiple Myeloma Trial CURE Magazine, 3 days ago Amgen's Kyprolis Fares Better than Velcade in Study - Analyst Blog Zacks.com, 3 days ago Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial News-Medical.Net, 3 days ago
Distractive auditory stimuli in the form of music in individuals with chronic obstructive pulmonary disease a systematic review
Background: Music has been used as a distractive auditory stimulus (DAS) in patients with chronic obstructive pulmonary disease (COPD), but its effects are unclear. This systematic review aimed to establish the effect of DAS on exercise capacity, ...CHEST, 12 hours ago Effects of One-Hour Training Course and Spirometry on the Ability of Physicians to Diagnose and Treat Chronic Obstructive Pulmonary Disease Plosone.org, 1 week ago Pain and its clinical associations in individuals with chronic obstructive pulmonary disease (COPD) a systematic review CHEST, 4 weeks ago Key research at CHEST 2014: Management of asthma, COPD Pharmacist.com, 1 month ago
The tendency toward 'either/or' thinking ( either cure or comfort) in traditional biomedical care paradigms does little to optimize care in advancing chronic illness. Calls for improved palliation in chronic lung disease mandate a review of related ...CHEST, 12 hours ago
PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment ...BioSpace, 13 hours ago Bristol-Myers Squibb (BMY) Grabs Record Fast Approval for Opdivo 3/5/2015 ClinicSpace, 13 hours ago FDA grants approval to nivolumab for non-small cell lung cancer Ecancer Medicalscience, 14 hours ago FDA Approves Opdivo for the Treatment of Patients with Previously Treated Metastatic Squamous NSCLC Finchannel.com, 15 hours ago
on your WebpageAdd Widget >Get your members hooked!